SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-035888
Filing Date
2021-07-07
Accepted
2021-07-06 17:38:08
Documents
13
Period of Report
2021-07-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-8k_20210706.htm   iXBRL 8-K 42376
2 EX-99.1 trvi-ex991_15.htm EX-99.1 92356
  Complete submission text file 0001564590-21-035888.txt   281659

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA trvi-20210706.xsd EX-101.SCH 5812
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20210706_lab.xml EX-101.LAB 20422
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20210706_pre.xml EX-101.PRE 12115
6 EXTRACTED XBRL INSTANCE DOCUMENT trvi-8k_20210706_htm.xml XML 3689
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 211075307
SIC: 2834 Pharmaceutical Preparations